Hemab Therapeutics (COAG) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.84 billion vs $1.53 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | RXRX |
|---|---|---|
| Share price | $39.29 | $2.45 |
| Market cap | $1.84B | $1.53B |
| 1-day change | -1.43% | -9.93% |
| YTD return | — | -40.10% |
| 1-year return | — | -41.25% |
| 5-year return | — | -87.04% |
| EPS (TTM) | $-3.55 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $74.68M |
| Revenue growth (YoY) | — | +26.92% |
| Net income (latest FY) | — | $-644.76M |
| Gross margin | — | 4.99% |
| Operating margin | — | -867.87% |
| Net margin | — | -863.35% |
| 52-week high | $55.42 | $5.24 |
| 52-week low | $23.00 | $2.44 |
| Distance from 52-week high | -29.11% | -53.24% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +60.35% | +176.33% |
| Average volume | 495.96K | 24.47M |
| Shares outstanding | 46.73M | 622.76M |
| Employees | 59 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
COAG vs RXRX FAQ
Which is bigger, Hemab Therapeutics or Recursion Pharmaceuticals?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.84B compared with $1.53B for Recursion Pharmaceuticals (RXRX).
Are Hemab Therapeutics and Recursion Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.